The clinical data is just the medium. The message is everything.
An agentic AI prototype — this platform will only get more informative and capable as time progresses.
Nine public data sources. One interpretive framework. From Health Canada filing through HTA review, pCPA negotiation, and provincial listing — the full regulatory-to-formulary journey, connected.
Track every drug from Health Canada submission through HTA review, pCPA negotiation, and provincial formulary listing. Real-time status with milestone timelines and calculated intervals.
Median stage durations, conversion rates, and provincial listing lags — benchmarked by therapeutic area. Know where your drug stands before the conversation starts.
A Gemini-powered intelligence layer that interprets raw pipeline data into plain-language strategic narratives. Ask questions, receive analysis grounded in the live database.
The access theatre is global. RxLumen monitors Most Favoured Nation pricing cascades, international reference pricing across PMPRB comparator countries, and real-time HTA signals from NICE, G-BA, PBAC, and HAS. What happens in Washington and Brussels does not stay there.
Sentinel — a guard posted to stand watch and identify what is approaching before it arrives.
Continuous surveillance of nine Canadian data sources and global pricing signals. The platform watches the system so you do not have to — identifying what changed, what it means, and what is coming next.
A strategist who reviews the message to ensure it aligns with what payers need to hear. Bridging the gap between data and message — where access is won or lost.
Pharmacoeconomists, data scientists, and strategists bridging the gap between regulatory approval and provincial reimbursement. Sign in to access the platform, or request access to join.
To enquire about engaging the HLS team's market access advisory services, please use the request form or contact us directly.